← Back to Search

Other

MBL949 Arm 4 for Obesity

Phase 2
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to day 169
Awards & highlights

Study Summary

This trial is testing a new drug to see if it's safe and effective for weight loss in obese people with or without diabetes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to day 169
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to day 169 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change-from-baseline in weight
Frequency and severity of Adverse Events

Trial Design

6Treatment groups
Active Control
Placebo Group
Group I: MBL949 Arm 4Active Control1 Intervention
One dose A followed by seven doses B of MBL949
Group II: MBL949 Arm 1Active Control1 Intervention
One dose C followed by two doses E followed by five doses D of MBL949
Group III: MBL949 Arm 5Active Control1 Intervention
One dose C followed by two doses E followed by five doses F of MBL949
Group IV: MBL949 Arm 2Active Control1 Intervention
Two doses C followed by six doses D of MBL949
Group V: MBL949 Arm 3Active Control1 Intervention
One dose G followed by seven doses D of MBL949
Group VI: PlaceboPlacebo Group1 Intervention
MBL949 Arm 1, MBL949 Arm 2 and placebo to be enrolled in a 1:1:1 ratio MBL949 Arm 3, MBL949 Arm 4 and placebo to be enrolled in a 1:1:1 ratio If MBL949 Arm 1 is tolerated, MBL949 Arm 5 to be enrolled with a 2:1 ratio (MBL:placebo) within each stratum. MBL949 arm 5 will have 12 participants and 6 participants added to placebo arm

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,854 Previous Clinical Trials
4,197,397 Total Patients Enrolled
6 Trials studying Obesity
793 Patients Enrolled for Obesity

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the eligibility criteria for participating in this clinical experiment?

"To take part in this research, patients must be between 18 and 60 years of age and have a diagnosis of obesity. We are hoping to enrol 106 individuals for the duration of the trial."

Answered by AI

Are recruitment efforts ongoing for this research trial?

"As per clinicaltrials.gov, this medical trial is still open for recruitment of patients. It first appeared on February 10th 2022 and was recently modified on April 5th 2022."

Answered by AI

Is the age eligibility for this trial restricted to those over 45 years of age?

"Precisely speaking, the enrollment criteria for this medical trial necessitates that applicants are between 18 and 60 years old. Moreover, there are 203 studies available to those under 18 while 595 trials cater to individuals over 65."

Answered by AI

How many locales are hosting this experiment?

"At present, 4 different medical centres have opened their doors to participants of this trial. These locations are based in Miami Beach, Dallas and Morehead City among others; thus it is advised that those wishing to take part select the clinic closest to them so as to abate travel costs."

Answered by AI

Has the MBL949 Arm 4 been given a regulatory green light by the FDA?

"Although there is limited evidence to suggest the efficacy of MBL949 Arm 4, its safety has been determined by our team at Power as a 2 due to Phase 2 trials."

Answered by AI

What is the total number of individuals participating in this experiment?

"Affirmative. Per the information present on clinicaltrials.gov, this medical trial is currently accepting applications. This study was first made public on February 10th 2022 and has been updated as recently as April 5th 2022. 106 participants are sought from 4 distinct locations for the experiment to take place."

Answered by AI

Who else is applying?

What state do they live in?
Ohio
Texas
Tennessee
How old are they?
18 - 65
What site did they apply to?
Novartis Investigative Site
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
1
2
0

What questions have other patients asked about this trial?

How long does this trial last?
PatientReceived 1 prior treatment

Why did patients apply to this trial?

How responsive is this trial?

Average response time
  • < 2 Days
Most responsive sites:
  1. Novartis Investigative Site: < 48 hours
Typically responds via
Email
Recent research and studies
clinicaltrials.govStudy
Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM
2022. "Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05199090.
~40 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top